Genocea Biosciences (NASDAQ:GNCA) Receives New Coverage from Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Rating) in a note issued to investors on Wednesday. The firm set a “sell” rating on the biotechnology company’s stock.

Genocea Biosciences Price Performance

The company has a market cap of $6,000.00, a P/E ratio of -0.01 and a beta of 1.61. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.35 and a quick ratio of 1.35. Genocea Biosciences has a 12 month low of $0.00 and a 12 month high of $0.00.

Genocea Biosciences Company Profile

(Get Rating)

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor.